Your browser doesn't support javascript.
loading
Development and validation of a machine learning-supported strategy of patient selection for osteoarthritis clinical trials: the IMI-APPROACH study.
Widera, Pawel; Welsing, Paco M J; Danso, Samuel O; Peelen, Sjaak; Kloppenburg, Margreet; Loef, Marieke; Marijnissen, Anne C; van Helvoort, Eefje M; Blanco, Francisco J; Magalhães, Joana; Berenbaum, Francis; Haugen, Ida K; Bay-Jensen, Anne-Christine; Mobasheri, Ali; Ladel, Christoph; Loughlin, John; Lafeber, Floris P J G; Lalande, Agnès; Larkin, Jonathan; Weinans, Harrie; Bacardit, Jaume.
Afiliação
  • Widera P; School of Computing, Newcastle University, Newcastle, UK.
  • Welsing PMJ; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Danso SO; School of Computing, Newcastle University, Newcastle, UK.
  • Peelen S; Lygature, Utrecht, the Netherlands.
  • Kloppenburg M; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Loef M; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Marijnissen AC; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • van Helvoort EM; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Blanco FJ; Institute of Biomedical Research, University Hospital of A Coruña, A Coruña, Spain.
  • Magalhães J; Institute of Biomedical Research, University Hospital of A Coruña, A Coruña, Spain.
  • Berenbaum F; APHP Hospital Saint-Antoine, Paris, France.
  • Haugen IK; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Bay-Jensen AC; Nordic Bioscience, Herlev, Denmark.
  • Mobasheri A; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Ladel C; Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland.
  • Loughlin J; Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
  • Lafeber FPJG; Department of Joint Surgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Lalande A; World Health Organization Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liege, Belgium.
  • Larkin J; BioBone B.V., Amsterdam, Netherlands.
  • Weinans H; Bioscience Institute, Newcastle University, International Centre for Life, Newcastle, UK.
  • Bacardit J; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Osteoarthr Cartil Open ; 5(4): 100406, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37649530
ABSTRACT

Objectives:

To efficiently assess the disease-modifying potential of new osteoarthritis treatments, clinical trials need progression-enriched patient populations. To assess whether the application of machine learning results in patient selection enrichment, we developed a machine learning recruitment strategy targeting progressive patients and validated it in the IMI-APPROACH knee osteoarthritis prospective study.

Design:

We designed a two-stage recruitment process supported by machine learning models trained to rank candidates by the likelihood of progression. First stage models used data from pre-existing cohorts to select patients for a screening visit. The second stage model used screening data to inform the final inclusion. The effectiveness of this process was evaluated using the actual 24-month progression.

Results:

From 3500 candidate patients, 433 with knee osteoarthritis were screened, 297 were enrolled, and 247 completed the 2-year follow-up visit. We observed progression related to pain (P, 30%), structure (S, 13%), and combined pain and structure (P â€‹+ â€‹S, 5%), and a proportion of non-progressors (N, 52%) ∼15% lower vs an unenriched population. Our model predicted these outcomes with AUC of 0.86 [95% CI, 0.81-0.90] for pain-related progression and AUC of 0.61 [95% CI, 0.52-0.70] for structure-related progression. Progressors were ranked higher than non-progressors for P â€‹+ â€‹S (median rank 65 vs 143, AUC = 0.75), P (median rank 77 vs 143, AUC = 0.71), and S patients (median rank 107 vs 143, AUC = 0.57).

Conclusions:

The machine learning-supported recruitment resulted in enriched selection of progressive patients. Further research is needed to improve structural progression prediction and assess this strategy in an interventional trial.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Osteoarthr Cartil Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Osteoarthr Cartil Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido